icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
N1quf5BRPSBR1Wmx